P. 132

An Urban Experience
U. Ggier1
1University of Pennsylvania, Veterinary Hospital, Philadelphia, USA
CANINE TRANSFUSION MEDICINE – An Update for Your Busy Practice
Urs Giger, Prof. Dr. med. vet. MS FVH
Dipl. ACVIM & ECVIM-CA (Internal Medicine) & Dipl.
ECVCP (Clinical Pathology)
School of Veterinary Medicine, University of Pennsylvania, Philadelphia
Veterinary clinicians play a key role in providing safe
and effective transfusion therapy. Blood typing is clinically important to ensure blood compatibility and therefore is recommended for any dog in need of a transfusion or considered to become a blood donor. Moreover, previously transfused dogs also should
be crossmatched. Unless blood typing is performed regularly in practice, blood may be sent to a clinical pathology laboratory for typing. Different viewpoints exist regarding the extent and methods used for compatibility testing.
Canine Blood Types
Blood types are genetic markers on erythrocyte surfaces that are antigenic and species speci c. A set of blood types of two or more alleles makes up a blood group system. Dogs have likely more than a dozen blood group systems mostly known as dog erythrocyte antigens (DEA). However, there is no DEA 2 blood group and some may be rather labeled high frequency or common red blood cell (RBC) antigens (e.g. DEA 4) and some have not yet received a DEA designation (e.g. Dal). Canine erythrocytes are either positive or negative for a blood type (e.g., DEA 4+ or DEA 4-), and these blood types are likely codominantly inherited. The DEA 1 system was thought to be an exception with DEA 1.1 (A1), DEA 1.2 (A2) and potentially DEA 1.3 (A3) being allelic. Thus, a dog could apparently be DEA 1.1+ or DEA 1.1- and DEA 1.1- dogs can be DEA 1.2+ or
DEA 1.2-. However, these studies were based upon weak polyclonal antibodies (DEA 1.1 and 1.X) requiring Coombs’ reagents. Recent studies with a monoclonal antibody showed that the DEA 1 blood group is a continuum from DEA 1- to weakly to strongly DEA 1+; hence DEA 1.2 typing is no longer offered. The degree of DEA 1 expression is constant and DEA 1+ appears to be
dominantly inherited. A recent survey in North America indicates that most dogs are either DEA 1- or strongly DEA 1+ with fewer dogs being weakly to moderately DEA 1+. The biochemical structure of the DEA 1 remains still unknown, but a genome wide association study has identi ed a likely single locus.
Recent surveys revealed that the Dal- type is not restricted to Dalmatians but is also seen in Doberman Pinschers, Lhasa Apsos and Shih Tzus and thus
typing for this blood type is becoming more important particularly for those requiring multiple transfusions. In a related study dogs from North America were screened for two new blood types, preliminarily called Kai 1 and Kai 2. Most dogs were Kai 1+ and only few dogs were Kai 2+ or Kai 1-/Kai2-. The clinical importance is yet to be determined albeit anecdotally dogs can develop anti- Kai 1 alloantibodies. The PennGen Laboratory currently offers Dal and Kai 1 and Kai 2 typing.
The clinically most important canine blood type is DEA
1, which elicits a strong alloantibody response after sensitization of a DEA 1- dog by a transfusion and thus can be responsible for a transfusion reaction in a DEA
1- dog previously transfused with DEA 1+ blood. It is currently unknown if DEA 1- dogs are equally sensitized by weakly to strongly DEA 1+ blood, or if weakly DEA
1+ dogs are sensitized by strongly DEA 1+ blood. Furthermore, transfusion reactions against other blood types or common antigens have rarely been observed and reported. They include reactions against the DEA
4, Dal, Kai 1 and other common RBC antigens; other clinically important blood types may be found in the future. No reagents currently are available against several antigens or are only available on a limited basis, and additional blood types continue to be recognized. Only limited surveys on the frequency of these blood types have been reported, which suggest possible geographic and breed-associated differences.
Strongly antigenic blood types are of great clinical importance because they can elicit a potent alloantibody response. These alloantibodies may be of the immunoglobulin G (IgG) or IgM class and may be hemagglutinins or hemolysins. Based upon experimental and clinical data, dogs can become sensitized after receiving a mismatched transfusion (i.e., a blood unit positive for one or more blood types not found on the recipient’s RBCs). There are no clinically important, naturally occurring alloantibodies (also known as isoantibodies) present before sensitization of a dog with a transfusion. Sensitizing dogs in experimental studies in the 1950s led to the documentation of some transfusion reactions caused by blood group incompatibilities and to the characterization of new blood types.

   130   131   132   133   134